Germany
ACADIA Pharmaceuticals Inc (ACAD) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Strategic Adjustments
Total Revenue: $242 million, up 46% year-over-year.DAYBUE Net Product Sales: $84.6 million, up 11% sequentially.NUPLAZID Net Product Sales: $157.4 million, up